M
Michael Drues
2
APPEARANCES
2
PODCASTS
012
DEC 30
JAN 6
JAN 13
JAN 20
JAN 27
FEB 3
FEB 10
FEB 17
FEB 24
MAR 3
MAR 10
MAR 17
MAR 24
MAR 31
APR 7
APR 14
APR 21
APR 28
MAY 5
MAY 12
MAY 19
MAY 26
JUN 2
JUN 9
JUN 16
JUN 23
JUN 30
JUL 7
JUL 14
JUL 21
JUL 28
AUG 4
AUG 11
AUG 18
AUG 25
SEP 1
SEP 8
SEP 15
SEP 22
SEP 29
OCT 6
OCT 13
OCT 20
OCT 27
NOV 3
NOV 10
NOV 17
NOV 24
DEC 1
DEC 8
DEC 15
DEC 22
DEC 29
JAN 5
JAN 12
JAN 19
JAN 26
FEB 2
FEB 9
FEB 16
FEB 23
MAR 2
MAR 9
MAR 16
MAR 23
MAR 30
APR 6
APR 13
APR 20
APR 27
MAY 4
MAY 11
MAY 18
MAY 25
JUN 1
JUN 8
JUN 15
JUN 22
JUN 29
JUL 6
JUL 13
JUL 20
JUL 27
AUG 3
AUG 10
AUG 17
AUG 24
AUG 31
SEP 7
SEP 14
SEP 21
SEP 28
OCT 5
OCT 12
OCT 19
OCT 26
NOV 2
NOV 9
NOV 16
Nov 13, 2026
Michael Drues, President at Vascular Sciences
J
5:27Jesús E. MorenoHOST
And we can talk about sample size or double blind or some of the technical aspects of how do you design the trial when you're dealing with a medical device.
M
5:41Michael DruesGUEST
I'm happy to address all of those points, Jesus, but let me get to those in just a moment.
M
5:48Michael DruesGUEST
I just want to share a couple more pieces of advice with regard to your first question, another of the very, very significant differences.
M
5:57Michael DruesGUEST
between medical devices versus drugs, perhaps from a regulatory perspective, the single most significant difference is where we set the bar in terms of safety and efficacy.
M
6:08Michael DruesGUEST
In other words, in the drug world, as probably many of your audience knows, we require substantial evidence of safety and efficacy.
M
6:18Michael DruesGUEST
Whereas in the medical device world, we require reasonable evidence of safety and efficacy.
M
6:24Michael DruesGUEST
Now, if you – I don't mean you personally, but if people think that the only difference between substantial versus reasonable is semantics, they really do not understand the world in which we live, quite frankly.
36 MINS LATER
J
42:08Jesús E. MorenoHOST
And that is, how can a clinical team structure the data gathering in such a way that it maximizes clinical insight without over committing to a rigorous endpoint that could backfire during a pivotal trial further down the line.
#476: Part 2: FDA Guidance: What We Should Expect in 2027
M
23:04Michael DruesGUEST
Yeah, so once again, and I can't emphasize this point enough, in my view, all guidance, indeed all regulation, including the Code of Federal Regulations, is under construction.
M
23:19Michael DruesGUEST
And I would think, Eddie, and that you as well as most people would probably agree with me on that.
M
23:24Michael DruesGUEST
We don't want regulation that we write it down today, and it will never change for a million years.
10 MINS LATER
